1. A compressed solid oral dosage form comprising a) an active substance containing an effective amount of valsartan, b) pharmaceutically acceptable additives suitable for the manufacture of solid oral dosage forms by compression, wherein the active substance is present in an amount of more than 35 wt.% In terms of the total mass of a solid oral dosage form； and where the effective amount of valsartan is 40 mg, 80 mg or 160 mg. 2. Compressed solid oral dosage form according to claim 1, where the amount of active substance is from 45 to 65 wt.%. 3. The compressed solid oral dosage form according to claim 1 or 2, wherein the active substance contains an effective amount of valsartan and an effective amount of hydrochlorothiazide (HCTA). The compressed solid oral dosage form according to claim 1 or 2, comprising a standard dose of valsartan of approximately 80 mg and a standard dose of HCTA of 12.5 mg or 25 mg. The compressed solid oral dosage form according to claim 1 or 2, comprising a standard dose of valsartan of approximately 160 mg and a standard dose of HCTA of 12.5 mg or 25 mg. The compressed solid oral dosage form according to claim 1 or 2, which comprises microcrystalline cellulose as a pharmaceutically acceptable additive. The compressed solid oral dosage form according to claim 1 or 2, which comprises crosslinked polyvinylpyrrolidone (PVP) as a pharmaceutically acceptable additive. The compressed solid oral dosage form according to claim 6, where the amount of microcrystalline cellulose is from 15 to 40 wt.%, Preferably from 20 to 301. Спрессованная твердая оральная дозируемая форма, включающаяа) действующее вещество, содержащее эффективное количество вальсартана, иб) фармацевтически приемлемые добавки, пригодные для изготовления твердых оральных дозируемых форм прессованием, где при этом действующее вещество присутствует в количестве, составляющем более 35 масс.% в пересчете на общую массу твердой оральной дозируемой формы； и где эффективное количество вал
